# Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

> **NCT04456361** · EARLY_PHASE1 · UNKNOWN · sponsor: **Instituto de Medicina Regenerativa** · enrollment: 9 (estimated)

## Conditions studied

- ARDS, Human
- Covid-19

## Interventions

- **BIOLOGICAL:** Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords

## Key facts

- **NCT ID:** NCT04456361
- **Lead sponsor:** Instituto de Medicina Regenerativa
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-16
- **Primary completion:** 2025-02-15
- **Final completion:** 2025-11-15
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456361, "Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04456361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*